Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward

AIDS Patient Care and STDs

Volumn 29, Issue 7, 2015, Pages 389-399

  Lo, Ying Ru ^a   Chu, Carissa ^b,c   Ananworanich, Jintanat ^d,e   Excler, Jean Louis ^d,e   Tucker, Joseph D ^c,f  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NORTH CAROLINA PROJECT CHINA   (China)

^d US Military HIV Research Program   (United States)

^e HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; NAMED GROUPS BY OCCUPATION; NONHUMAN; PRE-EXPOSURE PROPHYLAXIS; STAKEHOLDER; VERTICAL TRANSMISSION; CONSUMER; HIV INFECTIONS; RESEARCH; TRENDS;

AIDS VACCINES; ANTI-HIV AGENTS; CONSUMER PARTICIPATION; HIV INFECTIONS; HUMANS; PRE-EXPOSURE PROPHYLAXIS; RESEARCH;

EID: 84934285482     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2014.0348     Document Type: Article

References (139)

1. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009;360:692-698.
2. Yukl SA, Boritz E, Busch M, et al. Challenges in detecting HIV persistence during potentially curative interventions: A study of the Berlin patient. PLoS Pathog 2013;9:e1003347.
3. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013;369:1828-1835.
4. National Institute of Allergy and Infectious Diseases, National Institutes of Health. "Mississippi baby" now has detectable HIV, researchers find. NIH News, 2014. Available at: http://www.niaid.nih.gov/news/newsreleases/2014/Pages/MississippiBabyHIV.aspx (Last accessed July 19, 2014).
5. Henrich TJ, Hanhauser E, Marty FM, et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: Report of 2 cases. Ann Intern Med 2014;161:319-327.
6. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013;9:e1003211.
7. Purcell DF, Elliott JH, Ross AL, et al. Towards an HIV cure: Science and debate from the International AIDS Society 2013 symposium. Retrovirology 2013;10:134.
8. Deeks SG, Autran B, Berkhout B, et al. Towards an HIV cure: A global scientific strategy. Nat Rev Immunol 2012;12:607.
9. Tucker JD, Rennie S. Social and ethical implications of HIV cure research. AIDS 2014;28:1247-1250.
10. Cremin I, Alsallaq R, Dybul M, et al. The new role of antiretrovirals in combination HIV prevention: A mathematical modelling analysis. AIDS 2013;27:447-458.
11. Excler JL, Robb ML, Kim JH. HIV-1 vaccines: Challenges and new perspectives. Hum Vaccin Immunother 2014;10:1734-1746.
12. Mamotte N, Wassenaar D, Koen J, et al. Convergent ethical issues in HIV/AIDS, tuberculosis and malaria vaccine trials in Africa: Report from the WHO/UNAIDS African AIDS Vaccine Programme's Ethics, Law and Human Rights Collaborating Centre consultation, 10-11 February 2009, Durban, South Africa. BMC Med Ethics 2010;11:3.
13. Esparza J, Osmanov S, Kallings LO, et al. Planning for HIV vaccine trials: The World Health Organization perspective. AIDS 1991;5:S159-S163.
14. Excler JL, Tomaras GD, Russell ND. Novel directions in HIV-1 vaccines revealed from clinical trials. Curr Opin HIV AIDS 2013;8:421-431.
15. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-2220.
16. Robb ML, Rerks-Ngarm S, Nitayaphan S, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: A post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis 2012;12:531-537.
17. Newman PA, Logie C, James L, et al. "Speaking the dialect": Understanding public discourse in the aftermath of an HIV vaccine trial shutdown. Am J Public Health 2011;101:1749-1758.
18. Rerks-Ngarm S, Brown AE, Khamboonruang C, et al. HIV/AIDS preventive vaccine 'prime-boost' phase III trial: Foundations and initial lessons learned from Thailand. AIDS 2006;20:1471-2479.
19. Excler JL, Kochhar S, Kapoor S, et al. Preparedness for AIDS vaccine trials in India. Indian J Med Res 2008;127:531-538.
20. Cohen J. AIDS research. More woes for struggling HIV vaccine field. Science 2013;340:667.
21. Burton DR, Desrosiers RC, Doms RW, et al. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science 2004;303:316.
22. Iaccino E, Schiavone M, Fiume G, et al. The aftermath of the Merck's HIV vaccine trial. Retrovirology 2008;5:56.
23. Plotkin SA. Sang Froid in a time of trouble: Is a vaccine against HIV possible? J Int AIDS Soc 2009;12:2.
24. Chen RT, Hu DJ, Dunne E, et al. Preparing for the availability of a partially effective HIV vaccine: Some lessons from other licensed vaccines. Vaccine 2011;29:6072-6078.
25. Kelley RT, Hannans A, Kreps GL, et al. The Community Liaison Program: A health education pilot program to increase minority awareness of HIV and acceptance of HIV vaccine trials. Health Educ Res 2012;27:746-754.
26. Cameron MP, Newman PA, Roungprakhon S, et al. The marginal willingness-to-pay for attributes of a hypothetical HIV vaccine. Vaccine 2013;31:3712-3717.
27. International AIDS Vaccine Initiative. The potential impact of an AIDS vaccine in low- and middle-income countries. 2012. http://www.iavi.org/Information-Center/Publications/Pages/The-Potential-Impact-of-an-AIDS-Vaccine-in-Low-and-Middle-Income-Countries.aspx (Last accessed May 25, 2014).
28. Andersson KM, Stover J. The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand. Vaccine 2011;29:6092-6099.
29. Nagelkerke NJ, Hontelez JA, de Vlas SJ. The potential impact of an HIV vaccine with limited protection on HIV incidence in Thailand: A modeling study. Vaccine 2011;29:6079-6085.
30. Andersson KM, Paltiel AD, Owens DK. The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: Examining the RV144 trial results. Vaccine 2011;29:6107-6112.
31. Schwartlander B, Stover J, Hallett T, et al. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet 2011;377:2031-2041.
32. International AIDS Vaccine Initiative. Exploring the potential cost/benefit. Available at: http://www.iavi.org/Information-Center/Publications/Pages/AIDS-Vaccines-Exploring-the-Potential-Cost-Benefit.aspx (Last accessed May 25, 2014).
33. Jones A, Cremin I, Abdullah F, et al. Transformation of HIV from pandemic to low-endemic levels: A public health approach to combination prevention. Lancet 2014;384:272-279.
34. Lo YR, Nguyen TTT, Srikantiah P, Excler JL, Ghidinell, M, Narain JP. AIDS in Asia and the Pacific. In: HIV/AIDS in the Post-HAART Era: Manifestations, Treatment, and Epidemiology. 2011 ed. Shelton, CT: People's Medical Publishing House, 2011.
35. Nitayaphan S, Ngauy V, O'Connell R, et al. HIV epidemic in Asia: Optimizing and expanding vaccine development. Expert Rev Vaccines 2012;11:805-819.
36. Pitisuttithum P, Rerks-Ngarm S, O'Connell RJ, Kim JH, Excler JL. An HIV vaccine for South-East Asia - Opportunities and challenges. Vaccines 2013;1:348-366.
37. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-2599.
38. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367:399-410.
39. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013;381:2083-2090.
40. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367:423-434.
41. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med 2015;372: 509-518.
42. Okwundu CI, Uthman OA, Okoromah CA. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst Rev 2012;7:CD007189.
43. Jiang J, Yang X, Ye L, et al. Pre-exposure prophylaxis for the prevention of HIV infection in high risk populations: A meta-analysis of randomized controlled trials. PLoS One 2014;9:e87674.
44. AVAC. Global Advocacy for HIV Prevention. Available at: http://www.avac.org/sites/default/files/resource-files/PrEP-Trials-and-Demonstration-Projects-Nov2014.pdf (Last accessed April 26, 2014).
45. McGowan I. An overview of antiretroviral pre-exposure prophylaxis of HIV infection. Am J Reprod Immunol 2014;71:624-630.
46. United States Food and Drug Administration. FDA approves first drug for reducing the risk of sexually acquired HIV infection. 2014. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm (Last accessed May 26, 2014).
47. WHO. Guidance on pre-exposure oral prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: Recommendations for use in the context of demonstration projects. Geneva: Switzerland. 2012. http://www.ncbi.nlm.nih.gov/pubmed/23586123 (Last accessed December 7, 2014).
48. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2013. World Health Organization, Geneva, Switzerland. Geneva: World Health Organization. 2013. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727-eng.pdf?ua=1 (Last accessed December 7, 2014).
49. WHO. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. Geneva: World Health Organization. 2014. http://www.who.int/hiv/pub/guidelines/keypopulations/en/ (Last accessed December 7, 2014).
50. Centers for Disease Control and Prevention. Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morb Mortal Wkly Rep 2012;61:586-589.
51. Centers for Disease Control and Prevention. Update to interim guidance for preexposure prophylaxis (PrEP) for the prevention of HIV infection: PrEP for injecting drug users. MMWR Morb Mortal Wkly Rep 2013;62:463-465.
52. McMahon JM, Myers JE, Kurth AE, et al. Oral preexposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: Opportunities and challenges. AIDS Patient Care STDS 2014;28:462-474.
53. Ahmad K. Trial of antiretroviral for HIV prevention on hold. Lancet Infect Dis 2004;4:597.
54. Cohen J. Cambodia: Can a drug provide some protection? Science 2003;301:1660.
55. Cohen J. AIDS research. Cambodian leader throws novel prevention trial into limbo. Science 2004;305:1092.
56. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013;381:2083-2090.
57. Singh JA, Mills EJ. The abandoned trials of pre-exposure prophylaxis for HIV: What went wrong? PLoS Med 2005;2:e234.
58. Kim SC, Becker S, Dieffenbach C, et al. Planning for pre-exposure prophylaxis to prevent HIV transmission: Challenges and opportunities. J Int AIDS Soc 2010;13:24.
59. WHO. Report of a consultation: Preparing for Pre Exposure Prophylaxis (PrEP) Results: From Research to Implementation. WHO Press, 2009.
60. Forum for Collaborative HIV Research. Pre-exposure trials working group. Available at: http://www.hivforum.org/projects/prevention/biomedical-prevention/253-prep (Last accessed December 7, 2014).
61. Buchbinder SP, Liu A. Pre-exposure prophylaxis and the promise of combination prevention approaches. AIDS Behav 2011;15:S72-S79.
62. Paxton LA, Hope T, Jaffe HW. Pre-exposure prophylaxis for HIV infection: What if it works? Lancet 2007;370:89-93.
63. Buchbinder S. HIV epidemiology and prevention interventions. Top HIV Med 2007;15:26-30.
64. Okwundu CI, Okoromah CA. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst Rev 2009:CD007189.
65. Vissers DC, Voeten HA, Nagelkerke NJ, et al. The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: A simulation study. PLoS One 2008;3:e2077.
66. van de Vijver DA, Nichols BE, Abbas UL, et al. Pre-exposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: A comparison of mathematical models. AIDS 2013;27:2943-2951.
67. WHO. Report of a consultation: Preparing for pre-exposure prophylaxis (PrEP) results: From research to implementation. Geneva: World Health Organization. 2010. http://www.who.int/hiv/pub/arv/9789241599795/en/ (Last accessed April 13, 2014).
68. Grohskopf LA, Chillag KL, Gvetadze R, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr 2013;64:79-86.
69. Patton C, Kim HJ. The cost of science: Knowledge and ethics in the HIV pre-exposure prophylaxis trials. J Bioeth Inq 2012;9:295-310.
70. Wheelock A, Eisingerich AB, Ananworanich J, et al. Are Thai MSM willing to take PrEP for HIV prevention? An analysis of attitudes, preferences and acceptance. PLoS One 2013;8:e54288.
71. Galea JT, Kinsler JJ, Salazar X, et al. Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: Barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS 2011;22:256-262.
72. Michael N. Oral preexposure prophylaxis for HIV - Another arrow in the quiver? N Engl J Med 2010;363.
73. van Griensven F, Thienkrua W, McNicholl J, et al. Evidence of an explosive epidemic of HIV infection in a cohort of men who have sex with men in Thailand. AIDS 2013;27:825-832.
74. Beyrer C, Baral SD, van Griensven F, et al. Global epidemiology of HIV infection in men who have sex with men. Lancet 2012;380:367-377.
75. Jain S, Oldenburg CE, Mimiaga MJ, et al. Subsequent HIV infection among men who have sex with men who used non-occupational post-exposure prophylaxis at a Boston Community Health Center: 1997-2013. AIDS Patient Care STDS 2015;29:20-25.
76. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006;368:505-510.
77. Hammer SM. Antiretroviral treatment as prevention. N Engl J Med 2011;365:561-562.
78. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505.
79. Anglemyer A, Horvath T, Rutherford G. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. JAMA 2013;310:1619-1620.
80. Granich R, Crowley S, Vitoria M, et al. Highly active antiretroviral treatment as prevention of HIV transmission: Review of scientific evidence and update. Curr Opin HIV AIDS 2010;5:298-304.
81. Granich R, Gupta S, Suthar AB, et al. Antiretroviral therapy in prevention of HIV and TB: Update on current research efforts. Curr HIV Res 2011;9:446-469.
82. Kahn JG, Marseille EA, Bennett R, et al. Cost-effectiveness of antiretroviral therapy for prevention. Curr HIV Res 2011;9:405-415.
83. Gupta S, Granich R, Suthar AB, et al. Global policy review of antiretroviral therapy eligibility criteria for treatment and prevention of HIV and tuberculosis in adults, pregnant women, and serodiscordant couples. J Acquir Immune Defic Syndr 2013;62:e87-e97.
84. Mayer K, Gazzard B, Zuniga JM, et al. Controlling the HIV epidemic with antiretrovirals: IAPAC consensus statement on treatment as prevention and preexposure prophylaxis. J Int Assoc Provid AIDS Care 2013;12:208-216.
85. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-926.
86. WHO. WHO handbook for guideline development. Geneva: World Health Organization. 2012. http://apps.who.int/iris/bitstream/10665/75146/1/9789241548441-eng.pdf (Last accessed December 7, 2014).
87. Cohen MS, McCauley M, Sugarman J. Establishing HIV treatment as prevention in the HIV Prevention Trials Network 052 randomized trial: An ethical odyssey. Clin Trials 2012;9:340-347.
88. Killen J, Harrington M, Fauci AS. MSM, AIDS research activism, and HAART. Lancet 2012;380:314-316.
89. Treatment Action Group. Talk about a revolution. Available at: http://www.treatmentactiongroup.org/tagline/1998/December/talk-about-revolution (Last accessed December 7, 2014).
90. Cairns GS, Smith Z. HIV treatment as prevention - Launch of community consensus statement. 2014. Available at http://www.hivt4p.org/ (Last accessed February 12, 2015).
91. Cohen MS, Holmes C, Padian N, et al. HIV treatment as prevention: How scientific discovery occurred and translated rapidly into policy for the global response. Health Aff (Millwood) 2012;31:1439-1449.
92. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: A mathematical model. Lancet 2009;373:48-57.
93. WHO. WHO-NIH Informal consultation on antiretroviral treatment as HIV prevention: Implementation science in Asia. Geneva: World Health Organization. 2012. http://www.who.int/hiv/pub/meetingreports/tasp-meeting-report/en/ (Last accessed December 7, 2014).
94. WHO. Guidance on couples HIV testing and counselling - Including antiretroviral therapy for treatment and prevention in serodiscordant couples. Geneva: World Health Organization. 2012. Available at: http://www.who.int/hiv/pub/guidelines/9789241501972/en/ (Last accessed December 7, 2014).
95. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2013. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultand adolescentgl.pdf (Last accessed April 16, 2014).
96. The Korean Society for AIDS. The 2013 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans. Infect Chemother 2013;45:455.
97. Ministry of Health France. Rapport 2013 sur la prise en charge médicale des personnes vivant avec le VIH. Available at: http://www.sante.gouv.fr/rapport-2013-sur-la-prise-en-charge-medicale-des-personnes-vivant-avec-le-vih.html (Last accessed April 26, 2014).
98. De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries. JAMA 2000;283:1175-1182.
99. Cambiano V, O'Connor J, Phillips AN, et al. Antiretroviral therapy for prevention of HIV transmission: Implications for Europe. Euro Surveill 2013;18:20647.
100. Shaffer N, Bulterys M, Simonds RJ. Short courses of zidovudine and perinatal transmission of HIV. N Engl J Med 1999;340:1042-1043.
101. Mansergh G, Haddix AC, Steketee RW, et al. Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African Developing country setting. JAMA 1996;276:139-145.
102. Shaffer N, Abrams EJ, Becquet R. Option B + for prevention of mother-to-child transmission of HIV in resourceconstrained settings: Great promise but some early caution. AIDS 2014;28:599-601.
103. Dabis F, Msellati P, Meda N, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: A double-blind placebo-controlled multicentre trial. DI-TRAME Study Group. Diminution de la Transmission Mere-Enfant. Lancet 1999;353:786-792.
104. Phanuphak P, Cooper DA, Lange JM. Clinical trials in Asia. AIDS 1998;12:S163-S167.
105. Phanuphak P. Ethical issues in studies in Thailand of the vertical transmission of HIV. N Engl J Med 1998;338:834-835.
106. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 1999;353:773-780.
107. Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: A randomised trial. Lancet 1999;353:781-785.
108. Futterman D, Shea J, Besser M, et al. Mamekhaya: A pilot study combining a cognitive-behavioral intervention and mentor mothers with PMTCT services in South Africa. AIDS Care 2010;22:1093-1100.
109. Dunlap J, Foderingham N, Bussell S, et al. Male involvement for the prevention of mother-to-child HIV transmission: A brief review of initiatives in East, West, and Central Africa. Curr HIV/AIDS Rep 2014;11:109-118.
110. UNAIDS. Global plan toward the elimination of new HIV infections among children by 2015 and keeping their mothers alive, 2011-2015. Geneva: UNAIDS (2011). http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/20110609-jc2137-global-planelimination-hiv-children-en.pdf (Last accessed December 7, 2014).
111. UNICEF, WHO. Guidance on global scale-up of the prevention of mother to child transmission of HIV: towards universal access for women, infants and young children and eliminating HIV and AIDS among children. Geneva, Switzerland, 2007. Available at: http://www.unicef.org/aids/files/PMTCT-enWEBNov26.pdf (Last accessed April 11, 2015).
112. The Interagency Task Team on the Prevention and Treatment of HIV Infection in Pregnant Women, Mothers and Children. About IATT. Background and history. Available at: http://www.emtct-iatt.org/backgroundhistory (Last accessed April 28, 2014).
113. Ackerman Gulaid L, Kiragu K. Lessons learnt from promising practices in community engagement for the elimination of new HIV infections in children by 2015 and keeping their mothers alive: Summary of a desk review. J Int AIDS Soc 2012;15:17390.
114. Kohler PK, Ondenge K, Mills LA, et al. Shame, guilt, and stress: Community perceptions of barriers to engaging in prevention of mother to child transmission (PMTCT) programs in western Kenya. AIDS Patient Care STDS 2014;28:643-651.
115. UNAIDS. Twelve recommendations following a discussion about the 'Mississippi baby' (2013). Available at http://www.unaids.org/sites/default/files/media-asset/JC2531-12recommendations-en-0.pdf (Last accessed February 12, 2015).
116. UNICEF. The Interagency Task Team on the Prevention and Treatment of HIV Infection in Pregnant Women, Mother and Children. IATT Member Organizations. Available at: http://www.emtct-iatt.org/iatt-member-organizations/ (Last accessed April 23, 2014).
117. Ananworanich J, Schuetz A, Vandergeeten C, et al. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One 2012;7:e33948.
118. Ananworanich J, Puthanakit T, Suntarattiwong P, et al. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS 2014;28:1015-1020.
119. Cellerai C, Harari A, Stauss H, et al. Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term nonprogressors. PLoS One 2011;6:e18164.
120. Zeng M, Haase AT, Schacker TW. Lymphoid tissue structure and HIV-1 infection: Life or death for T cells. Trends Immunol 2012;33:306-314.
121. Zeng M, Southern PJ, Reilly CS, et al. Lymphoid tissue damage in HIV-1 infection depletes naive T cells and limits T cell reconstitution after antiretroviral therapy. PLoS Pathog 2012;8:e1002437.
122. McMichael AJ, Borrow P, Tomaras GD, et al. The immune response during acute HIV-1 infection: Clues for vaccine development. Nat Rev Immunol 2010;10:11-23.
123. Ananworanich J VC, Chomchey N, Phanuphak N, Ngauy V, Sekaly R, Robb M, Michael N, Kim JH, Chomont N on behalf of the RV254/SEARCH 010 Study Group. Early ART intervention restricts the seeding of the HIV reservoir in long lived central memory CD4 T cells [Abstract 47]. Paper presented at: 20th Conferences on Retroviruses and Opportunistic Infections, March 3-6, 2013; Atlanta, United States of America.
124. th International AIDS Conference. July 22-27 2012. Washington, United States. (Last accessed February 12, 2015).
125. Kawichai S, Celentano D, Srithanaviboonchai K, et al. NIMH Project Accept (HPTN 043) HIV/AIDS community mobilization (CM) to promote mobile HIV voluntary counseling and testing (MVCT) in rural communities in Northern Thailand: Modifications by experience. AIDS Behav 2012;16:1227-1237.
126. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012;487:482-485.
127. Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014;370:901-910.
128. Henrich EH, Sirignano MN, et al. HIV-1 rebound following allogeneic stem cell transplantation and treatment interruption. Abstract 144LB 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014). Boston, United States, 2014.
129. AIDS Advisory Committee of People with HIV/AIDS. The Denver Principles. Available at: http://www.nlm.nih.gov/survivingandthriving/education/documents/OB2216-DenverPrinciples.pdf (Last accessed December 7, 2014).
130. Wachter RM. AIDS, activism, and the politics of health. N Engl J Med 1992;326:128-133.
131. Morin SF, Maiorana A, Koester KA, et al. Community consultation in HIV prevention research: A study of community advisory boards at 6 research sites. J Acquir Immune Defic Syndr 2003;33:513-520.
132. Shubis K, Juma O, Sharifu R, et al. Challenges of establishing a Community Advisory Board (CAB) in a low-income, low-resource setting: Experiences from Bagamoyo, Tanzania. Health Res Policy Syst 2009;7:16.
133. Henderson GE, Juengst ET, King NM, et al. What research ethics should learn from genomics and society research: Lessons from the ELSI Congress of 2011. J Law Med Ethics 2012;40:1008-1024.
134. Petruney T, Harlan SV, Lanham M, et al. Increasing support for contraception as HIV prevention: Stakeholder mapping to identify influential individuals and their perceptions. PLoS One 2010;5.
135. Davidson J, Moiya N, Plange N. HIV/AIDS stakeholder mapping in Papau New Guinea. Geneva: UNAIDS, 2004.
136. Schmeer K. Stakeholder Analysis Guidelines. Geneva: WHO, 2011.
137. Shirey MR. Stakeholder analysis and mapping as targeted communication strategy. J Nurs Adm 2012;42:399-403.
138. Ancker S, Rechel B. HIV/AIDS policy-making in Kyrgyzstan: A stakeholder analysis. Health Policy Plan 2015; 30:8-18.
139. Powers CM, Grieger KD, Hendren CO, et al. A web-based tool to engage stakeholders in informing research planning for future decisions on emerging materials. Sci Total Environ 2013;470-471:660-668.